Browse by Author or Creator

Article

• Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., Elsheik, S., Hadjimichael, E., Villasanti, N., Adams, S. E., Cunnell, M., Metheringham, R. L., Brentville, V. A., Machado, L., Daniels, I., Gijon, M., Hannaman, D. and Durrant, L. G. (2018) Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology. 7(6) 2162-4011.
• Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., Elsheik, S., Hadjimichael, E., Villasanti, N., Adams, S. E., Cunnell, M., Metheringham, R. L., Brentville, V. A., Machado, L., Daniels, I., Gijon, M., Hannaman, D. and Durrant, L. G. (2018) Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. OncoImmunology. 7(6), e1433516. 2162-4011.
• Durrant, L. G., Ottensmeier, C., Lorigan, P., Mulatero, C., Plummer, R., Cunell, M., Metheringham, R. L., Brentville, V. A. and Machado, L. (2014) Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. Cancer Research. 74(19 Sup) 0008-5472.

Book Section

• Durrant, L. G., Xue, L., Machado, L., Metheringham, R. L. and Brentville, V. A. (2014) DNA vaccines. In: Rees, R. C. (ed.) Tumor Immunology and Immunotherapy. Oxford: Oxford University Press. pp. 251-264.

Monograph

• Poole, H., Sixsmith, J., Parkes, J., Ward, A., Pyer, M., Campbell, J., Machado, L., Rehling, T., Youell, J., Carter, J., Oyebode, J., O’Malley, M., Anthony, K., Rogers, S., Jones, J., Siddons, L., Smith, L.-A., Kay, A. D., Fraser, M., Score, J., El Khoury, L., Hameed, A., Albalbeisi, N., Durrant, L. G., Al-Zubaidi, R., Al-Rayahi, I., da Silva, K. and Taylor, J. (2017) Health and wellbeing amongst older people research in Northamptonshire.

Conference or Workshop Item

• Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S. and Durrant, L. G. (2016) Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK, 06-09 November 2016.
• Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S. and Durrant, L. G. (2016) Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, University of Birmingham, 2016-11-06 - 2016-11-09.
• Patel, P. M., Durrant, L. G., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Cunnell, M., Metheringham, R. L., Brentville, V. A., Machado, L., Daniels, I. and Hannaman, D. (2014) Phase I trial of ImmunoBody in melanoma patients. Poster presented to: 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, McCormick Place, Chicago, Illinois, 30 May - 03 June 2014. (Unpublished)
• Machado, L., Moseley, P., Moss, R., Nolan, C., Rampage, J., Chan, S. and Durrant, L. G. (2014) High-mobility group protein 1 (HMGB1) is an independent predictor of poor survival in ovarian cancer. Poster presented to: National Cancer Research Institute (NCRI) Cancer Conference, Liverpool, UK, 02-05 November 2014. Also presented at: British Society for Immunology Annual Congress (BSI2014), Brighton, UK, 01-04 December 2014 (Unpublished)